Search results
Nektar Therapeutics' (NASDAQ:NKTR) investors will be pleased with their stellar 130% return over the...
Simply Wall St. via Yahoo Finance· 14 hours agoNektar Therapeutics (NASDAQ:NKTR) shareholders might be concerned after seeing the share price drop...
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Zacks via Yahoo Finance· 10 months agoNektar Therapeutics NKTR reported a loss of 27 cents per share for the second quarter of 2023, which...
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Zacks via Yahoo Finance· 3 months agoNektar Therapeutics NKTR reported an adjusted loss of 22 cents per share for the fourth quarter of...
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance· 2 years agoNektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased...
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
Zacks via Yahoo Finance· 8 months agoNektar NKTR announced a partnership with Cellular Biomedicine to develop its pipeline candidate,...
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Zacks via Yahoo Finance· 1 year agoNektar Therapeutics NKTR reported a loss (excluding non-cash goodwill and other impairment charges)...
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
Zacks via Yahoo Finance· 1 year agoNektar Therapeutics NKTR, which is focused on the development of treatments utilizing its PEGylation...
Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoNektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript May 9, 2023 Operator: Good day...
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
Zacks via Yahoo Finance· 1 year agoThe new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The...
Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of...
Simply Wall St. via Yahoo Finance· 11 months agoKey Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is...